Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer is a phase 2 interventional study registered as NCT00563836 by Neovii Biotech, with 41 participants recorded, started 2007-11 and reaching its primary completion in 2008-09. Interventions recorded: Catumaxomab. Conditions recorded: Ovarian Cancer, Epithelial Ovarian Cancer.

Linked to the drug Catumaxomab because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.